Key result
Newer oral anticoagulants provide stable anticoagulation at a fixed dose without laboratory monitoring, showing improvements in safety and efficacy over conventional Vitamin K antagonists.
Why the study?
Conventional anticoagulants have limitations including wide dose-response variations, delayed onset and offset, narrow therapeutic ranges, and need for frequent monitoring, prompting the review of FDA-approved newer oral anticoagulants.
Do newer oral anticoagulants offer improved safety and efficacy compared to conventional anticoagulants in patients requiring anticoagulation?
Do newer oral anticoagulants offer improved safety and efficacy compared to conventional anticoagulants in patients requiring anticoagulation?
Newer oral anticoagulants provide a more convenient, stable therapeutic regimen with improved safety and efficacy compared to conventional anticoagulants, without the need for routine laboratory monitoring.
Answers are grounded in this paper and cite their sources.
May support convenient anticoagulation without monitoring; hypothesis-generating from Level 5 review and needs prospective validation.
The conventionally used anticoagulants for the treatment of thromboembolism include unfractionated heparin, low molecular weight heparin, fondaparinux and Vitamin K antagonists such as warfarin, phencoumarol. Though they were considered the milestones in anticoagulation therapy, their use in clinical practice is limited due to its certain patient related issues such as wide variations in dose response relationship, delayed onset and offset of action, narrow therapeutic range of clinical effectiveness, frequent monitoring and dose adjustment. In order to overcome the above drawbacks of conventional anticoagulants, FDA approved Newer Oral Anticoagulants that provide stable anticoagulation at a fixed dose without the need for laboratory control, making it more convenient therapeutic regimen. In this review, the use of newer oral anticoagulant drugs in current clinical practice as well as the facts and concerns related to its use, safety and efficacy in patients with concomitant diseases like antiphospholipid syndrome, chronic kidney disease and patients undergoing cardio version is focused. Moreover, the various newer developments and ongoing trials in the field of anticoagulation were also discussed. The emergence of new reversal agents that are currently under development and its role in paediatric populations will be also an added advantage for its development. In short, the use of new anticoagulants had shown improvements in safety and efficacy as well as they offer greatest promise and opportunity for the replacement of Vitamin K Antagonists and other conventional agents.
No takes yet. Share an insight, caveat, or question.
Morries et al. (2020) conducted a review in Thromboembolism. Newer Oral Anticoagulants vs. Conventional anticoagulants (e.g., Vitamin K antagonists, heparin) was evaluated. Newer oral anticoagulants provide stable anticoagulation at a fixed dose without laboratory monitoring, showing improvements in safety and efficacy over conventional Vitamin K antagonists.
Synapse has enriched 10 related papers. Consider them for comparative context: